To keep the final cost of medicines as low as possible for patients, MMV negotiates hard.
Using a robust procurement process when engaging with research service providers and partners, we get the best prices – in one case achieving a cost saving of more than 73% compared to the original proposal. We also aim to contain production costs by seeking the most efficient routes of synthesis for our medicines – beyond reductions expected from economies of scale.
Through our mission and reputation we are able to engage service providers who are happy to offer reduced rates. In this way, we are able to maximize the value of every donor dollar to our highly focused mission and develop high-quality medicines that are affordable for vulnerable populations.
Updated July 2017